Halozyme Therapeutics, Inc. (HALO) Appoints Harry J. Leonhardt, Esq. As Senior Vice President, General Counsel And Chief Compliance Officer

SAN DIEGO, April 13, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the appointment of Harry J. Leonhardt, Esq., as senior vice president, general counsel and chief compliance officer, reporting to Dr. Helen Torley, president and chief executive officer.

Mr. Leonhardt brings more than 30 years of corporate legal, intellectual property, compliance, business development and mergers and acquisitions experience to Halozyme, with an extensive background in the biotechnology sector. He most recently served as senior vice president of Legal and Compliance, and corporate secretary for Amylin Pharmaceuticals, a biotech company acquired by Bristol Myers Squibb in 2012. At Halozyme, he will be responsible for all legal, compliance and intellectual property matters.

"As Halozyme executes our drug development strategies and prepares for the future commercialization of our oncology pipeline, I am pleased to welcome a biotech veteran of Harry's caliber to our management team," said Dr. Torley. "His experience will be invaluable to our team and will help facilitate the continued growth and success of our business."

Prior to joining Amylin, Mr. Leonhardt served as senior vice president, general counsel and corporate secretary for Senomyx; executive vice president of Business Development, general counsel and corporate secretary at Genoptix, Inc.; and senior vice president, general counsel and secretary for Nanogen, Inc. He also held positions of increasing responsibility at Allergan, Inc. including head of worldwide litigation and general counsel for European Operations. Early in his career, Mr. Leonhardt was an attorney at the Los Angeles office of Lyon & Lyon where he represented a number of prominent clients in the biotechnology and pharmaceutical industries. He received his Bachelor of Science degree from the University of the Sciences in Philadelphia and his Juris Doctorate from the University of Southern California Law Center.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor.  PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events, competitive conditions and the continuation of the Halozyme-Janssen and other collaborations. These and other factors that may result in differences are discussed in greater detail in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 2, 2015.

Schond Greenway
[email protected]

Jim Mazzola
[email protected]